GSK's vaccines outperform other groups, achieving 11% growth in Q2


After making a big bet on the field, GlaxoSmithKline ($GSK) continues to post gains in vaccines. In second-quarter results released Wednesday, the British pharma reported that its vax group notched the highest growth of the company’s three major units as it neared £1 billion for the quarter.

GSK vaccines grew 11% in the second quarter, besting pharmaceutical growth of 2% and consumer healthcare growth of 7%. In total, the unit reeled in £960 million ($1.26 billion) in Q2 and £1.84 billion ($2.47 billion) in the first half.

To get there, GSK’s vaccines needed standout performances in Europe and internationally to offset a U.S. decline of 2%. In an earnings statement, GSK attributed a portion of the U.S. slip to “adverse movement in the CDC stockpile.” In Europe, GSK’s vaccines grew 11% thanks to Bexsero boosts in private markets, among other factors. Elsewhere around the world, the pharma enjoyed a 20% increase in vax sales.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The results follow first-quarter growth of 23% on a reported basis and 14% on a pro forma basis for vaccines, boosted during the period by former Novartis ($NVS) shots Menveo and Bexsero. And the upward trend is exactly what GSK execs want to see following the company’s massive asset swap with Novartis in which it traded away its oncology assets for the Swiss pharma’s vaccines stall.

With more than a year of integration behind it, GSK said “costs for these major restructuring programmes are expected to reduce significantly in 2017 with only residual charges thereafter.” Vaccines pitched in £270 worth of profit in the second quarter, good for a 28.1% core operating margin.

That's a far cry from those figures shortly after the deal's close last year, when GSK's vax group achieved £161 million in profit at a 12.1% operating margin. At the time, CEO Andrew Witty said the unit was impacted by a "higher than anticipated cost base" from the Novartis deal.

- here's the release

Related Articles:
GSK's vaccine operating profit, margin dive on Novartis fold-in
GSK's vax revenues jump in 2015 while profit, margin slip
GSK's vaccine unit sees revenue, profit jump in Q3


Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.